Brain disorders (Amsterdam, Netherlands)最新文献

{"title":"Transcranial magnetic stimulation alleviates cognitive dysfunction after stroke by inhibiting microglial transformation","authors":"Yi-ning Zhao ,&nbsp;Zhen-Kun Gao ,&nbsp;Xing-yu Zhang ,&nbsp;Ping-ping Han ,&nbsp;Xia Bi","doi":"10.1016/j.dscb.2025.100287","DOIUrl":"10.1016/j.dscb.2025.100287","url":null,"abstract":"<div><div>Intermittent theta burst stimulation (iTBS) has been demonstrated to be a efficacious intervention for mitigating neurological deficits following a stroke. Nevertheless, there remains a paucity of animal studies that investigate the neurobiological mechanisms contributing to its therapeutic effects. Accordingly, the present experiments focused on the effects of iTBS on behavioral and neuropathology in ischemia/reperfusion (I/R)-injured rats and explored the underlying mechanisms. A rat model of I/R injury was established through middle cerebral artery occlusion (MCAO). Sprague-Dawley (SD) rats were randomly assigned to three groups: a sham group, an MCAO group, and an iTBS + MCAO group (administered once daily for ten consecutive days). There were 18 rats in each group, and cognitive function, myelin regeneration, microglia, inflammation, and MAPK signaling pathway expression were evaluated in each group.</div><div>The findings revealed that iTBS enhanced the performance of animals in Y-maze and Open Field Test and facilitated the recuperation of cognitive functions following I/R injury. Furthermore, iTBS mitigated myelin damage, facilitated myelin regeneration, simultaneously induced the conversion of microglia to a neuroprotective M2 phenotype and significantly reduced the intensity of pro-inflammatory factor storm. Subsequent studies demonstrated that iTBS enhanced cognitive function in rats subjected to I/R injury, which was partially attributed to the suppression of the ERK1/2 and JNK signaling cascades. This inhibition promoted the transformation of M2 microglia, suppressed inflammation, and created a conducive microenvironment for myelin regeneration.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"20 ","pages":"Article 100287"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145221575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic and metabolic diagnostic profile of children presented with spastic paraplegia/diplegia","authors":"Nebal Waill Saadi ,&nbsp;Basma Adel Ibrahim ,&nbsp;Qusay Abed Fahad ,&nbsp;Henry Houlden ,&nbsp;Rahema Mohammad ,&nbsp;Mina Zamani ,&nbsp;Adel A. Kareem ,&nbsp;Ali Kadhim Al-Husseinawi ,&nbsp;Hayder Kadhim Jabbar ,&nbsp;Saif Hamed Farhan ,&nbsp;Omar A.Thu Noon ,&nbsp;Mays Al-Tai","doi":"10.1016/j.dscb.2025.100294","DOIUrl":"10.1016/j.dscb.2025.100294","url":null,"abstract":"<div><h3>Background</h3><div>Spastic paraplegia/diplegia in children may be an early manifestation of underlying neurogenetic disorders which are often underdiagnosed in clinical practice. The aim of the study is to investigate the genetic causes and clinical characteristics of neurogenetic disorders presenting with spastic diplegia/paraplegia in children.</div></div><div><h3>Patients and methods</h3><div>A retrospective analysis of medical records of children aged 0 – 18 years who were reported to have spastic paraplegia/diplegia as a core clinical feature with confirmed genetic etiologies was conducted. Data on demographic and clinical features, neuroimaging, and available genetic testing results were analyzed.</div></div><div><h3>Results</h3><div>A total of 53 patients fulfilled the study eligibility criteria. The study comprises 27 males (50.9 %) with male:female ratio 1.04:1. Mean age of onset is approximately 3 years. Walking difficulty/gait disturbance/posturing of limbs were the commonest presenting features (29, 54.7 %). The two commonest neurological disorders identified were leukodystrophies/genetic leukoencephalopathies (20, 37.7 %) and hereditary spastic paraplegia (15, 28 %). The most frequent abnormalities found in neuroimaging were signal abnormalities in the white matter and thinning of corpus callosum. This study contributes with 23 novel mutations that were not reported in other non-Iraqi patients.</div></div><div><h3>Conclusions</h3><div>A comprehensive clinical approach to patients with spastic paraplegia/diplegia will aid in early diagnosis, targeted management, and improve counseling in pediatric neurology practice. We contribute to the regional and international data on the genetic spectrum of spastic paraplegia/diplegia.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"20 ","pages":"Article 100294"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145528023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Science of tomorrow: Unearthing hidden discoveries of cognitive enhancers","authors":"Meysam Mirzaei ,&nbsp;Zahra Razi ,&nbsp;Mohammad Hossein Morowvat","doi":"10.1016/j.dscb.2025.100290","DOIUrl":"10.1016/j.dscb.2025.100290","url":null,"abstract":"<div><div>Recent advancements in cognitive enhancers have paved the way for a new era in neuropharmacology and Cognitive Science, offering significant potential to enhance human cognition. This article provides a concise overview of current research on cognitive enhancers, with a focus on their mechanisms of action and related ethical considerations.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"20 ","pages":"Article 100290"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145417569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A robust multi-criteria decision-making approach for selecting optimal drugs in epilepsy treatment using the analytic hierarchy process","authors":"Hamzeh Ghorbani ,&nbsp;Hrachuhi Papyan ,&nbsp;Arsen Minasyan ,&nbsp;David A. Wood ,&nbsp;Parvin Ghorbani ,&nbsp;Simin Ghorbani ,&nbsp;Eduard Avagyan ,&nbsp;Steve Badakian ,&nbsp;Natali Minasian","doi":"10.1016/j.dscb.2025.100292","DOIUrl":"10.1016/j.dscb.2025.100292","url":null,"abstract":"<div><div>Epilepsy, a neurological disorder characterized by recurrent seizures, poses significant challenges in selecting the most appropriate antiseizure medication (ASM) due to the complex interplay of clinical, pharmacological, and patient-specific factors. This study applies the Analytic Hierarchy Process (AHP), a structured multi-criteria decision-making (MCDM) method, to systematically evaluate and prioritize key criteria in ASM selection. The criteria analyzed include seizure control efficacy, safety and tolerability, pharmacokinetics, age and comorbidities, drug interactions, cost, patient compliance, risk of dependency, and impact on quality of life. Based on a comprehensive literature review and the judgments of a multidisciplinary panel of thirty experts, including neurologists, pharmacologists, biostatisticians, health economists, epilepsy nurses, and academic researchers, a pairwise comparison matrix was developed to determine the relative importance of each factor. The analysis identified seizure control as the most critical criterion (weight = 0.143), followed by safety (0.129), pharmacokinetics (0.123), and patient age (0.111). Factors such as cost, compliance, and drug dependency also played notable but comparatively secondary roles. The integration of AHP into the decision-making process provides clinicians with a transparent and rational framework that accommodates multiple, often competing, variables to inform a personalized treatment strategy. This approach enhances the precision of clinical choices, particularly in complex cases, by aligning medication selection with both evidence-based findings and collective expert insight. Overall, the findings support the adoption of AHP as a valuable tool in epilepsy management, promoting more effective and individualized treatment decisions through the quantitative assessment of critical therapeutic factors.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"20 ","pages":"Article 100292"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145417568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report of individualized dose modifying practice with pulsed oral dexamethasone for mild chronic inflammatory demyelinating polyneuropathy: Could a lower dose suffice?","authors":"Kit Mun Loke ,&nbsp;Fu Liong Hiew","doi":"10.1016/j.dscb.2025.100281","DOIUrl":"10.1016/j.dscb.2025.100281","url":null,"abstract":"<div><div>Pulsed corticosteroid is highly effective in the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with the advantage of a higher potential in achieving therapy-free remission in comparison to immunoglobulin. More recently, fixed pulsed corticosteroid regime have been demonstrated to have better efficacy with fewer side effects than daily dosing. However, distinct gaps exist in current treatment guidelines on what is the best corticosteroid regimen. We illustrate a novel treatment perspective with an individualised pulsed oral dexamethasone dosing modifying method in 2 treatment-naïve patients with typical CIDP based on clinical response and side effect profiles. Both patients achieved remission on assessment with clinically validated CIDP disability and impairment scales. Dose reduction as early as the third month did not lead to clinical deterioration. The similarities between both patients were young females with no co-morbidities, early disease presentation, mild sensorimotor impairment, and functional disability at presentation and less aggressive disease progression. Therefore, in a selected group of CIDP patients, a lower cumulated corticosteroid dose may be sufficient to achieve clinical remission with individualized dosing modification. To the best of our knowledge, this innovative corticosteroid treatment insight for CIDP has not been described in the literature.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"20 ","pages":"Article 100281"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroprotective effects of natural products against doxorubicin-induced chemobrain: a narrative review of preclinical animal studies","authors":"Mehrnoush Vaez Salehy ,&nbsp;Parvin Babaei ,&nbsp;Zahra Nahavandi Ghaffarkandi ,&nbsp;Foad Ghazizadeh","doi":"10.1016/j.dscb.2025.100284","DOIUrl":"10.1016/j.dscb.2025.100284","url":null,"abstract":"<div><h3>Rationale</h3><div>Chemobrain/chemofog, or chemotherapy-related cognitive impairment (CRCI), is considered a prevalent long-term complication among survivors. Doxorubicin (DOX), a well-known anthracycline administered in various cancers, drew much attention regarding inducing animal chemobrain models. On the other hand, using natural compounds as a safe and promising strategy for mitigating many pathological conditions, including chemobrain, has become a trend.</div></div><div><h3>Objectives</h3><div>In this review, we focused on the reported neuroprotective effects of 16 naturally derived bioactives, including galangin, juglanin, rutin, quercetin, catechin, naringin, astaxanthin, polydatin, caffeic acid phenethyl ester, berberine, c-phycocyanin, omega-3 polyunsaturated fatty acids, alpha-lipoic acid, diosmin, thymoquinone, and curcumin against DOX-related cognitive deficit.</div></div><div><h3>Results</h3><div>Given the emphasis on learning, memory impairment, and exploratory behavior, our literature review suggests that reducing oxidative stress (OS), neuroinflammation, and apoptosis are core pathways. However, alterations in the levels of neurogenesis, synaptic plasticity, acetylcholine esterase (AChE) activity, and other less frequent processes such as autophagy, brain mitochondrial dysfunction, necroptosis, and nitrogenic stress have also been reported.</div></div><div><h3>Conclusion</h3><div>Beyond the value of the published studies, there is still an urgent need for further research to evaluate natural compounds around this phenomenon with additional mimicking of the clinical settings, using novel formulations, and investigating the new insights into the mechanisms involved.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"20 ","pages":"Article 100284"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145108095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting blink rate and pupil diameter from ADHD symptoms: Effects of white noise stimulation in an experimental study","authors":"Erica Jostrup ,&nbsp;Emma Claesdotter-Knutsson ,&nbsp;Pia Tallberg ,&nbsp;Göran Söderlund ,&nbsp;Peik Gustafsson ,&nbsp;Marcus Nyström","doi":"10.1016/j.dscb.2025.100289","DOIUrl":"10.1016/j.dscb.2025.100289","url":null,"abstract":"<div><h3>Background</h3><div>Children with ADHD are reported to have lower dopamine (DA) and norepinephrine (NE) levels compared to typically developing children. We exploratively investigated how blink rate and pupil diameter, which are considered to be proxies for DA and NE signaling, were related to ADHD symptom severity. Moreover, we tested whether this relation is modulated by auditory white noise stimulation, which has been suggested as a non-pharmacological treatment for children with ADHD.</div></div><div><h3>Method</h3><div>We measured blink rate and pupil diameter in 97 children with varying levels of ADHD symptoms during a 60 s fixation task. The task was performed with and without auditory white noise stimulation. The effect of white noise stimulation was evaluated in relation to symptom severity and task duration.</div></div><div><h3>Results</h3><div>We found no relationship between the level of ADHD symptom severity and blink rate or pupil diameter, nor did symptom severity interact with auditory white noise stimulation. However, pupil diameter was consistently larger throughout the entire task as a result of the noise stimulation, an effect driven by boys.</div></div><div><h3>Conclusions</h3><div>Blink rate and pupil diameter do not seem to be reliably associated with ADHD symptom severity. This association also did not change when applying white noise stimulation. However, given the larger pupil diameter of boys, sex should be considered in future studies using white noise stimulation.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"20 ","pages":"Article 100289"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145321269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence of hyperglycemia in patients on admission with acute stroke without prior history of diabetes mellitus and its impact on the outcome in Pakistan","authors":"Kainat Amjad,&nbsp;Malala Khan,&nbsp;Husnain Hashim,&nbsp;Saima Shafait,&nbsp;Saeed Arif","doi":"10.1016/j.dscb.2025.100283","DOIUrl":"10.1016/j.dscb.2025.100283","url":null,"abstract":"<div><h3>Background</h3><div>Acute stroke is a leading cause of disability and death worldwide, and hyperglycemia is frequently present at admission, often complicating patient outcomes (Williams, et al.). While the relationship between stroke and hyperglycemia has been widely studied in individuals with diabetes, limited evidence exists regarding its role in patients without a prior diagnosis of diabetes (Lau, et al.).</div></div><div><h3>Objective</h3><div>This study aimed to determine the prevalence of hyperglycemia in acute stroke patients without known diabetes and to evaluate its effect on short- and long-term outcomes in Pakistan.</div></div><div><h3>Method</h3><div>A retrospective review was conducted of acute stroke patients without pre-existing diabetes. Blood glucose levels at admission, hospital stay duration, and outcomes in terms of neurological recovery, functional independence, and mortality were analyzed.</div></div><div><h3>Results</h3><div>Of 378 patients, 25.4 % had pre-existing diabetes. Admission blood glucose testing showed that 35.2 % were hyperglycemic. A significant association was observed between glucose levels and prior diabetes status. Among hyperglycemic patients, 73 % had stress hyperglycemia, while 27 % had chronic hyperglycemia. Patients with hyperglycemia experienced longer hospital stays and higher disability scores, as measured by the Modified Rankin Scale (MRS), suggesting poorer recovery. Overall, 15.6 % of patients died during hospitalization, with admission hyperglycemia strongly associated with increased mortality.</div></div><div><h3>Conclusion</h3><div>Hyperglycemia at admission is common in stroke patients without diabetes and is linked to worse clinical outcomes, including prolonged hospitalization, greater disability, and higher mortality (Stead, et al.) [<span><span>3</span></span>]. These findings highlight the need for further studies to define the role of hyperglycemia in acute stroke management in both diabetic and non-diabetic populations.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"20 ","pages":"Article 100283"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145121289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The neurobiological and behavioral impacts of adulterants in drugs of abuse","authors":"Mason Hochstetler ,&nbsp;Anastasia Dodge ,&nbsp;Swarup Mitra","doi":"10.1016/j.dscb.2025.100296","DOIUrl":"10.1016/j.dscb.2025.100296","url":null,"abstract":"<div><div>This review examines how the presence of adulterants in drugs of abuse can disrupt the neurobiological, behavioral, and physiological processes associated with substance use disorder (SUD). Adulteration, the practice of adding foreign substances to illicit drugs to increase potency or profits, has dangerous and often life-threatening consequences for users. These pharmacologically active ingredients interact with neurobiological pathways in both brain and body, altering the addictive properties of the primary substance and complicating treatment efforts. This includes changes in neurotransmitter activity and alterations in brain circuitry, which increase the likelihood of continued substance use and relapse. In turn, behavioral outcomes are significantly affected, with individuals often experiencing cravings, impaired decision-making, precipitated overdose, and stronger compulsive drug-seeking behaviors. This review primarily highlights the non-abused adulterants and how pairing them with drugs of abuse can alter wide-ranging brain mechanisms. The analysis focuses primarily on preclinical studies while drawing connections to relevant clinical data when available to offer a comprehensive understanding of the impact of SUD on behavioral and physiological outcomes.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"20 ","pages":"Article 100296"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145528025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychosis preceding motor symptoms in Huntington’s disease: A psychiatric inpatient case series","authors":"Beatriz Fonseca Silva,&nbsp;Pedro Felgueiras,&nbsp;Tatiana Pessoa,&nbsp;Bárbara Moura,&nbsp;André Oliveira","doi":"10.1016/j.dscb.2025.100279","DOIUrl":"10.1016/j.dscb.2025.100279","url":null,"abstract":"<div><h3>Introduction</h3><div>Huntington’s Disease (HD) is a neurodegenerative condition associated with neuronal loss and atrophy in the caudate nucleus and putamen. The most prevalent disease manifestations include movement symptoms like chorea, a progressive cognitive decline and neuropsychiatric signs. Psychosis presenting before other symptoms is rare in HD and is often a confounding fator in differential diagnosis, evoking other psychiatric syndromes. We aim to report on three cases of HD that presented with psychotic symptomatology.</div></div><div><h3>Case description</h3><div>The three patients discussed displayed psychotic symptoms several years before the motor manifestations of the disease. In this context, they were all admitted in a psychiatric ward, despite the presence of family history, the clinical course and previous evaluations by Neurology.</div></div><div><h3>Discussion</h3><div>Possible mechanisms that explain the prevalence of psychotic symptoms in HD and their eventual emergence in earlier disease phases have been identified. Neglecting this fact might delay diagnosis and possible interventions in patients and their families (including, possibly, genetic testing). Although it is a rare clinical presentation of HD, signs like heavy family history of similar disease evolution should lead to a rigorous diagnostic workup.</div></div><div><h3>Conclusion</h3><div>Regarding these clinical cases, we highlight the importance of considering HD in patients with psychotic symptoms and suspicion of a hereditable disease. In fact, earlier differential diagnosis would allow better management of symptomatology. In these cases, treatment had to be readjusted considering the neurological implications, to improve the quality of life.</div></div>","PeriodicalId":72447,"journal":{"name":"Brain disorders (Amsterdam, Netherlands)","volume":"20 ","pages":"Article 100279"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}